Brii Bio H1 FY26 loss narrows 32.1% to RMB 101 million

• Brii Bio posted an IFRS net loss of RMB 101 million, narrowing 32.1% from a year earlier; basic loss per share improved to RMB 0.14.
• Other income fell 30.6% to RMB 19.5 million on lower bank interest income as time-deposit rates declined.
• R&D expenses dropped 16% to RMB 98.3 million, while administrative costs decreased 9.6% to RMB 52.6 million on lower employee costs.
• Other gains and losses swung to a RMB 30.5 million gain, driven by fair-value changes in equity investments.
• Cash and bank deposits totaled RMB 1.77 billion at June 30, down 8.8% since Dec. 31, with funding expected to last through 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12293440), on August 20, 2026, and is solely responsible for the information contained therein.